A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age
Latest Information Update: 09 May 2024
At a glance
- Drugs Elasomeran (Primary) ; V 503 (Primary)
- Indications COVID 2019 infections; Human papillomavirus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 09 May 2024 New source identified and integrated (European Clinical Trials Database:EudraCT2021-003591-13).
- 18 Dec 2023 Status changed from active, no longer recruiting to completed.
- 23 Mar 2023 Planned End Date changed from 9 Nov 2023 to 12 Jan 2024.